Clinical Trial: A Study of Mitragynine Formulations for Exercise-Induced Muscle Soreness in Healthy Adults

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809282) titled 'A Study of Mitragynine Formulations for Exercise-Induced Muscle Soreness in Healthy Adults' on Aug. 28.

Brief Summary: This Phase II randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and physical dependence potential of mitragynine-containing formulations after 28 days of use and assess their effects on exercise-induced muscle soreness in healthy adults. One hundred participants will be randomized in a 1:1:1:1 ratio to SpecioTea 20 mg, SpecioTea 40 mg, MitraPlex 20 mg, or placebo. Participants will complete an exercise challenge to induce delayed-onset muscle soreness (DOMS), undergo efficac...